IDMC 15
Meeting 2026

Scientific PROGRAM

May 26 to 30, 2026

Hôtel Le Montagnais,
Saguenay, Québec, Canada

Last update : May 24th 2026

Sponsorship

Platinum Sponsors

Myotonic Dystrophy Foundation

AVIDITY BIOSCIENCES
A Novartis Company

AFMTÉLÉTHON
CURE THROUGH INNOVATION

Dyne THERAPEUTICS

Gold Sponsors

EURO-DYMA
Myotonic Dystrophies

PepGen

MDSC
MUSCULAR DYSTROPHY CANADA
DYSTROPHIE MUSCULAIRE CANADA

ARTHEx biotech

CORAMH
Corporation de recherche et d'action sur les maladies héréditaires

Silver Sponsors

VERTEX

SAREPTA THERAPEUTICS

Bronze Sponsors

sanofi

axelys
Créons, innovons, pour prospérer.

MYOTONE DYSTROFIE EXPERTISECENTRUM
Maastricht UMC+ Radboudumc

CDM
Cure Myotonic Dystrophy
Support ♥ Awareness ♥ Research
CureDM.co.uk

Poster & Networking Sessions Sponsors

LUPIN NEUROSCIENCES

PepGen

Community Partners

Cell
ThéCell: Réseau de thérapie cellulaire, tissulaire et génique du Québec

Faculté de médecine
Université de Montréal

CHU Sainte-Justine
Le centre hospitalier universitaire mère-enfant
Université de Montréal

Tuesday, 26 May 2026

09:00 - 13:00	**Pharma Day with Euro-DyMA and MDF**
09:00 - 16:00	**Registration** Reception Hall
13:00 - 14:00	**Global alliance In-Person Meeting**
16:00 - 22:00	**Welcome Reception in La Baie** La Baie

Wednesday, 27 May 2026

08:00 - 16:00 **Registration**
Reception Hall

08:15 - 08:30 **Introduction**
La Montagnaise

08:30 - 09:00 **Invited Speakers - Past IDMC organizers**
La Montagnaise

09:00 - 10:00 **Session: Pathogenic Mechanisms I**
La Montagnaise

Single-Molecule Analysis Reveals Asymmetric CpG Methylation at the DM1 Locus Driven by Somatic Instability 80
Thomas D. Hoekman[1]
[1]Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands

Alternative Splicing of SORBS1 Affects Neuromuscular Junction Integrity in Myotonic Dystrophy Type 1 125
Morgan Gazzola[1] [1]Institut des cellules souches pour le traitement et l'étude des maladies monogéniques (I-Stem), Corbeil-Essonnes

Tissue-Specific Regulation of Full-Length MBNL1 via Alternative Transcriptional Termination 131
Katarzyna Taylor[1] [1]Laboratory of Gene Therapy, Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University in Poznań, Poland

Profibrotic Factors and Extracellular Matrix Remodeling Associated with Muscle Fibrosis in Myotonic Dystrophy Type 1 174
Preeti Kumari[1, 2]
[1]Massachusetts General Hospital, [2]Harvard Medical School

10:00 - 10:30 **Speed Dating**
La Montagnaise

10:30 - 12:15 **Poster Session with Coffee Break**
Tipi-tente-wigwam-Réserve Sud/Nord

Balance and coordination in myotonic dystrophy type 1 4
Sarah Mollet[1]
[1]University of Auckland

The FREEDOM-DM1 clinical trial demonstrated unprecedented splicing correction with single doses of PGN-EDODM1, with an acceptable safety profile. 5
Johanna Hamel[1] [1]University of Rochester

Differentiated Cognitive Profiles in Myotonic Dystrophy Type 1: A Cluster Analysis 6
Irati Larrañaga[1, 2] [1]Department of Clinical and Health Psychology and Research Methodology; Faculty of Psychology, University of the Basque Country (EHU), Donostia - San Sebastian, Spain, [2]Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain

Respiratory function in Myotonic dystrophy type 1- a prospective single center study 7
Olöf Eliasdóttir[1] [1]Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Blåa stråket 7, 41345, Gothenburg, Sweden

Investigating the basis of sleep dysregulation in myotonic dystrophy type 1 8
Belinda Pinto[1] [1]University of Florida

Harmonization and federated analysis of myotonic dystrophy registries to model heterogeneous disease trajectories. Results from the 287th ENMC International Workshop 9
Leandre Fontaine[1] [1]Maastricht University Medical Center

Responsiveness and the minimal clinically important difference of the DM1-ActivC in Myotonic Dystrophy type 1 10
Leandre la Fontaine[1] [1]Maastricht University Medical Center

	Uncovering DMPK-Dependent Mitochondrial Defects in Myotonic Dystrophy Type 1 Muscle Stem Cells Pauline Garcia[1, 2] [1]CHU Sainte Justine, [2]Département de Physiologie et Pharmacologie, Université de Montréal	214
	Integrated functional and multi-omic profiling of DM1 iPSC-derived cardiomyocytes Caroline Part[1, 2] [1]1. CHEO Research Institute, Ottawa, ON, Canada, [2]2. Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada	215
	Cancer Risk in Myotonic Dystrophy Martin Payne[1] [1]None	216
	Dosage of neurodegeneration biomarkers in the blood of myotonic dystrophy type I patients with or without type II Diabetes Nicolas SERGEANT[1] [1]Inserm UMRS1172, Univ. Lille, CHRU of Lille, Lille Neuroscience Research Center, Lille Neuro & Chemistry	217
	Integrating proteomics and structure prediction to determine the interactome of proteins involved in muscular dystrophies and myopathies Yasmine Amina Bachir[1] [1]INRS - Centre Armand-Frappier - Santé Biotechnologie, Unité mixte de recherche (UMR) INRS- UQAC en santé durable	218
	Cognitive and social decision-making skills in adult-onset Myotonic Dystrophy type 1 Maria Carolina Fontana Antunes de Oliveira[1] [1]Université Paris Cité - Memory, Brain and Cognition Laboratory (MC2 Lab)	219
	The GRIMN Biobank: A Longitudinal Biobank Coupling Biospecimens with Comprehensive Clinical Phenotyping in DM1 Melissa Verreault[1] [1]Groupe de recherche interdîsciplinaire sur les maladies neuromusculaires (GRIMN), Center for Research and Innovation of the Saguenay-Lac-St-Jean Integrated University Health and Social Services Center, Saguenay, Quebec, Canada	224
12:15 - 13:00	**Lunch** Totem Nord-Réserve Centre	
13:15 - 13:30	**Flash Talk** La Montagnaise	
	Investigating the basis of sleep dysregulation in myotonic dystrophy type 1 Belinda Pinto[1] [1]University of Florida	8
	A cross-sectional study exploring the alignment between patient-reported and biomechanical dysphagia outcomes in myotonic dystrophy type1 (DM1) Jodi Allen[1] [1]The National Hospital for Neurology and Neurosurgery, University College NHS Foundations Trust, UK	95
	Growth, development, and social participation in congenital and childhood-onset myotonic dystrophy type 1: A nationwide survey in Japan Yuzuha Ichimura[1] [1]Clinical Neurophysiology, The University of Osaka Graduate School of Medicine	119
	DM1 RAN Proteins Accumulate in Autopsy Brain Regions with Degenerative and Neuroinflammatory Changes and Promote Tau Aggregation in Neuronal Cells Monica Banez-Coronel[1] [1]University of Florida	190
	Advancing motor function assessment across childhood in congenital and childhood-onset DM1 Michael Kiefer[1] [1]Center for Inherited Myology Research, Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA	199
13:30 - 14:15	**Patient Engagement in Research** La Montagnaise	
14:15 - 15:00	**Session: Children with DM** La Montagnaise	
	Natural history of oropharyngeal dysphagia in children with congenital and childhood myotonic dystrophy type 1: a 3-year longitudinal cohort study Saskia Scholten[1] [1]Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Amalia Children's Hospital, Nijmegen, The Netherlands	40

	On the Move: Longitudinal Insights Advancing the Understanding of Motor Function in Paediatric Myotonic Dystrophy Type 1 Lynn Orriëns[1] [1]Department of Pediatric Neurology, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, the Netherlands	89
	Cognitive and Behavioral Impairment in Congenital and Childhood-Onset Myotonic Dystrophy Type 1: A Longitudinal Analysis Anna Falco[1] [1]The NeMO Center in Rome, U.O.C. Neuropsichiatria Infantile, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.	168
15:30 - 22:00	**Step Back in Time: The Story of Val-Jalbert and Saguenay–Lac-Saint-Jean** Val-Jalbert	

Thursday, 28 May 2026

08:00 - 16:00	**Registration** Reception Hall	
08:15 - 08:30	**Introduction** La Montagnaise	
08:30 - 09:00	**Invited Speaker - Roman H. Khonsari** La Montagnaise	
09:00 - 10:15	**Session: Development of Biomarkers and Clinical Outcome Assessments I** La Montagnaise	
	Clinical Validation of Socially Assistive Robot-Administered Physical Tests in Myotonic Dystrophy Type 1 Killian LACHAUX[1] [1]Département d'Informatique et Mathématique, Université du Québec à Chicoutimi, Chicoutimi, Québec, Canada.	31
	Multi-omic profiling stratified by the Splicing Index enables circulating biomarker discovery in myotonic dystrophy type 1 Melissa Hale[1] [1]Center for Inherited Myology Research, Department of Neurology, Virginia Commonwealth University, USA	118
	DM1-Hub registry: building a nationwide infrastructure to define the natural history of myotonic dystrophy type 1 Gisela Nogales-Gadea[1] [1]Badalona Neuromuscular Research Group (GRENBA), Germans Trias i Pujol Research Institute (IGTP), Badalona, Catalonia, Spain	156
	Cerebrospinal fluid multi-omic biomarkers of myotonic dystrophy type 1 Preeti Kumari[1] [1]Massachusetts General Hospital, Harvard Medical School	187
	Disease progression in Myotonic Dystrophy Type 2 Johanna Hamel[1] [1]University of Rochester Medical Center	207
10:15 - 10:45	**Coffee Break**	
10:45 - 11:30	**Session: Clinical Manifestations, Activity and Participation I** La Montagnaise	
	Cognitive and Social cognition functioning in adults with childhood myotonic dystrophy type 1 Simon-Pierre Gagnon[1, 2] [1]Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), [2]Faculté de médecine et des sciences de la santé, Université de Sherbrooke (UdS)	56
	A Multidimensional Profile of Dysphagia in Myotonic Dystrophy Type 1 (SwallowDM1) Jodi Allen[1] [1]The National Hospital for Neurology & Neurosurgery, University College London NHS Foundation Trust, UK	100
	Preimplantation Genetic Testing in Myotonic Dystrophy Type 1: Clinical Outcomes and Insights Johanna Bruijnes[1] [1]Department of Neurology and MHeNS School for Mental Health and Neuroscience, Maastricht University Medical Centre+, Maastricht, The Netherlands	126
11:30 - 12:45	**Session: Cell and Animal Models for DM** La Montagnaise	
	A repressible CUG repeat RNA mouse model to study the neurological manifestations and their reversibility in myotonic dystrophy type 1 Larissa Nitschke[1] [1]Baylor College of Medicine	11
	Bioengineered 3D Muscle Tissues Identify an MBNL1-Independent Mechanism of Calcitriol-Mediated Myotonia Rescue Juan M. Fernández-Costa[1, 2] [1]Institute for Bioengineering of Catalonia (IBEC), [2]Barcelona Institute of Science and Technology (BIST)	24
	Transcriptomic and molecular characterization of a neuronal mouse model for myotonic dystrophy type 1 (DM1) Juan D. Arboleda[1] [1]Department	108

	of Molecular Genetics & Microbiology, Center for NeuroGenetics, University of Florida, Gainesville FL 32610	
	Consequences of congenital myotonic dystrophy during neuromuscular development Caroline Hermitte[1] [1]Institut des cellules souches pour le traitement et l'étude des maladies monogéniques (I-Stem), Corbeil-Essonnes	122
	RNA and RAN Protein Gain-of-Function Effects in a Novel DM2 BAC Transgenic Mouse Model Hannah Golliher[1, 2] [1]Center for NeuroGenetics, University of Florida, [2]Department of Molecular Genetics and Microbiology, Univerity of Florida	179
12:45 - 13:45	**Lunch** Totem Nord-Réserve Centre	
13:45 - 15:00	**Session: Pathogenic Mechanisms II** La Montagnaise	
	Evidence of nuclear DMPK transcript degradation and cytoplasmic export in DM1 cells using dSTORM Super Resolution Microscopy Petter Hamilton-Stanley[1] [1]University of Nottingham	90
	Axon initial segment disruption and impaired vesicle transport reveal neuron-intrinsic mechanisms of brain dysfunction in DM1 Louison Daussy[1] [1]Sorbonne University, Inserm, Centre de Recherche en Myologie, Paris, France	128
	Toxic CUG RNA repeats disrupt developmentally regulated splicing in oligodendrocytes causing transient hypomyelination in a mouse model of myotonic dystrophy Gabriele Ordazzo[1] [1]Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France	134
	Converging mechanisms of DMPK and TCF4 CTG repeat expansions underpin Fuchs endothelial corneal dystrophy Christina Zarouchlioti[1] [1]UCL Institute of Ophthalmology, London, UK	162
	Autism-related traits in myotonic dystrophy type 1 Łukasz Sznajder[1] [1]University of Nevada, Las Vegas, NV, USA	165
15:00 - 15:15	**Flash Talk** La Montagnaise	
	Evaluating drug potential of macrolide azithromycin in Myotonic Dystrophy 1 (DM1) Tushar Ghosh[1] [1]University of Nottingham	85
	Methylation of CCG variant repeats is associated with heterogeneous methylation of CpG sites surrounding DMPK expansion in DM1 patients Jovan Pesovic[1] [1]Center for Human Molecular Genetics, University of Belgrade-Faculty of Biology, Belgrade, Serbia	173
	Development and Expert Evaluation of a Clinical Checklist for Adult Myotonic Dystrophy Type 1 Care Homira Osman[1] [1]Muscular Dystrophy Canada	186
	Apathy as a Distinct Executive Phenotype in Adult Myotonic Dystrophy Type 1 Melissa M. Dixon[1] [1]University of Utah	206
	Proteogenomic Discovery of Splice-Junction Peptides as Novel Biomarkers in Cerebrospinal Fluid of Myotonic Dystrophy Type 1 (DM1) Marwa Zafarullah[1] [1]Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA	210
15:15 - 16:15	**Late-Breaking session** La Montagnaise	
	Long-Read Sequencing Reveals Elevated Mitochondrial DNA Structural Variations Associated with Disease Severity in Myotonic Dystrophy Type 1 Wenhan Zhang[1, 2] [1]Fudan University, [2]Huashan Hospital, Fudan University	220
	Data from the initial cohort of the FREEDOM2-DM1 multiple-ascending	222

dose trial of PGN-EDODM1. James McArthur[1] [1]PepGen Inc., Boston, MA

Multi-Omics CSF Profiling Reveals CNS Dysfunction Candidate Biomarkers in Myotonic Dystrophy Type 1 (DM1) Marwa Zafarullah[1] [1]Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 223

16:15 - 19:00 **Poster and Networking Session**

Tipi-tente-wigwam-Réserve Sud/Nord

Balance and coordination in myotonic dystrophy type 1 Sarah Mollet[1] [1]University of Auckland 4

The FREEDOM-DM1 clinical trial demonstrated unprecedented splicing correction with single doses of PGN-EDODM1, with an acceptable safety profile. Johanna Hamel[1] [1]University of Rochester 5

Differentiated Cognitive Profiles in Myotonic Dystrophy Type 1: A Cluster Analysis Irati Larrañaga[1, 2] [1]Department of Clinical and Health Psychology and Research Methodology; Faculty of Psychology, University of the Basque Country (EHU), Donostia - San Sebastian, Spain, [2]Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain 6

Respiratory function in Myotonic dystrophy type 1- a prospective single center study Olöf Eliasdóttir[1] [1]Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Blåa stråket 7, 41345, Gothenburg, Sweden 7

Investigating the basis of sleep dysregulation in myotonic dystrophy type 1 Belinda Pinto[1] [1]University of Florida 8

Harmonization and federated analysis of myotonic dystrophy registries to model heterogeneous disease trajectories. Results from the 287th ENMC International Workshop Leandre Fontaine[1] [1]Maastricht University Medical Center 9

Responsiveness and the minimal clinically important difference of the DM1-ActivC in Myotonic Dystrophy type 1 Leandre la Fontaine[1] [1]Maastricht University Medical Center 10

Natural history of PR interval and QRS duration in Myotonic Dystrophy Type 1 David Bovenkerk[1] [1]1. Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands 12

Addressing gastrointestinal symptoms in myotonic dystrophy: consensus-based recommendations for clinical practice and research Saskia Scholten[1] [1]Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Amalia Children's Hospital, Nijmegen, The Netherlands 13

Investigating the role of the transcriptional kinase, CDK13, in mutant DMPK transcription and RNA foci formation. Jessie Brown[1] [1]University of Nottingham 14

Hepatic insulin resistance in myotonic dystrophy type 1 is highly associated with acquired factors HIROTO TAKADA[1] [1]NHO Aomori National Hospital 15

Intensive speech therapy training in people with myotonic dystrophy type 1. Simone Knuijt[1] [1]Donders institute for brain, cognition and behavior, Radboud university medical center, Department of rehabilitation, Nijmegen, the Netherlands. 16

Measurement properties and clinical relevance of outcome measures for myotonia in myotonic dystrophy type 1: protocol of the MyoMeasure study Elise Taken[1] [1]Radboud University Medical Center, the Netherlands 17

Assessment of sleep-wake patterns in adults with the infantile-onset form of myotonic dystrophy type 1: an actigraphy study Luc Laberge[1] [1]ÉCOBES - Recherche et transfert, Cégep de Jonquière 18

18:30 - 23:00	**Bites, Sips & Saguenay Vibes** Downtown Chicoutimi
18:30 - 23:00	**Special Activity for Trainees** CORAMH

Friday, 29 May 2026

08:15 - 08:30 **Introduction**
La Montagnaise

08:30 - 09:00 **Invited Speaker - Jason Robert Guertin**
La Montagnaise

09:00 - 10:00 **Session: Development of Biomarkers and Clinical Outcome Assessments II**
La Montagnaise

Developing digital endpoints to assess ambulation in DM1: analytical validation and feasibility of using a wearable sensor in daily living 61
Stéphane Motola[1] [1]Sysnav, Vernon, France

Beyond balance: exploring cerebellar cognition in Myotonic Dystrophy Type 1 132
Carola Rita Ferrari Aggradi[1] [1]NeMO Clinical Center, Milan, Italy

Cross-sectional and 3-year longitudinal analysis of RNA mis-splicing in vastus lateralis muscle in a DM1 cohort 141
Cécilia Légaré[1, 2, 3, 4] [1]Centre de Recherche du Centre Hospitalier de l'Université Laval (CR-CHUL), Axe Neurosciences, Université Laval, Québec City, Canada, [2]École des sciences de la réadaptation, Faculté de médecine, Université Laval, Québec, Canada, [3]Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Québec, Canada, [4]RNA Institute, College of Arts and Sciences, University at Albany-SUNY, Albany, NY 12222, USA

Multicenter Multimodal Imaging Reveals System-Level CNS Disruption in Pediatric Myotonic Dystrophy Type 1 203
Tahereh Kamali[1] [1]Stanford University

10:00 - 10:30 **Coffee Break**

10:30 - 11:30 **Session: Clinical Manifestations, Activity and Participation II**
La Montagnaise

Frailty in DM1: Prevalence and Associations with Disease-Specific Factors 3
Irati Larrañaga[1, 2] [1]Department of Clinical and Healthy Psychology and Research Methodology Psychology Faculty, University of the Basque Country, [2]Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.

Everyday Cognitive Failures in Myotonic Dystrophy Type 1 (DM1): A Longitudinal Study 86
STEFAN WINBLAD[1] [1]Department of Psychology, University of Gothenburg, Sweden

Vitamin D Deficiency and Respiratory Muscle Dysfunction in Myotonic Dystrophy Type 1 114
Daniel Jaraj[1] [1]Department of Neurology, Sahlgrenska University Hospital, Gothenburg university, Sweden

Identifying an Appropriate Patient-Reported Outcome Measure for Oropharyngeal Dysphagia in Myotonic Dystrophy Type 1 148
Claudia Côté[1, 2] [1]Université Laval, [2]GRIMN

11:30 - 12:30 **Session: Clinical Management, Rehabilitation and Quality of Life Improvement**
La Montagnaise

Energy Expenditure and the Accuracy of Predictive Equations in Myotonic Dystrophy Type 1 53
Isis B.T. Joosten[1] [1]Department of Neurology and School for Mental Health and Neuroscience, Maastricht University Medical Centre+, Maastricht, The Netherlands

Feasibility, acceptability and effects of a telerehabilitation-based Respiratory Training Program in Myotonic Dystrophy Type 1 71
Elie Fiogbé[1, 2, 3] [1]Groupe de recherche interdîsciplinaire sur les maladies neuromusculaires (GRIMN), Saguenay-Lac-St-Jean Integrated University Health and Social Services Center, Saguenay, Quebec, Canada, [2]School of Rehabilitation, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada,

	[3]Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS), Université de Sherbrooke, Québec, Canada	
	The Current Landscape of Perinatal Information Provision and Genetic Counseling in Congenital Myotonic Dystrophy Type 1 in Japan Ayumi Yonei[1] [1]Department of Genetic Counseling, The University of Osaka Hospital	74
	Impact of assisted reproductive technologies on reproductive outcomes in women with myotonic dystrophy: a retrospective study Patricia Garay-Albízuri[1, 2, 3] [1]Department of Neurology, Donostialdea Integrated Health Organisation, Osakidetza, San Sebastian, Spain, [2]Neuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, San Sebastian, Spain, [3]CIBERNED, CIBER, Spanish Ministry of Science & Innovation, Carlos III Health Institute, Madrid, Spain	183
12:30 - 13:30	**Lunch** Totem Nord-Réserve Centre	
13:30 - 14:45	**Session 5: Preclinical and Clinical Drug Development** La Montagnaise	
	Multiscale imaging uncovers xenogeneic regenerative capacity of human pericytes as a cell therapeutic vehicle Renée H.L. Raaijmakers[1, 2] [1]Radboud university medical center, Radboud Institute for Medical Innovation and Donders Institute for Brain Cognition and Behaviour, Department of Human Genetics, 6500 HB, Nijmegen, The Netherlands, [2]Radboud university medical center, Radboud Institute for Medical Innovation, Department of Medical BioSciences, 6500 HB, Nijmegen, The Netherlands	42
	Scaling therapeutic discovery in DM1: A validated high-throughput platform combining in vitro screening and machine learning Virginia Arechavala-Gomeza[1, 2] [1]Nucleic Acid Therapeutics for Rare Diseases (NAT-RD), Biobizkaia Health Research Institute, Barakaldo, Spain, [2]Ikerbasque, Basque Foundation for Science, Bilbao, Spain	82
	Tricyclo-DNA antisense oligonucleotide compounds to tackle toxic CUGexp-RNA in a mouse model of Myotonic Dystrophy type 1 Julie FAGIOLI[1] [1]Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France	83
	Sensor-Regulated Decoy Gene Therapy for Myotonic Dystrophy Type 1 Ludovic Arandel[1] [1]Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France	135
	Interventionally Contracting Somatic CTG Repeat Expansions as a Disease-Modifying Strategy for Myotonic Dystrophy Type 1 Shuqian Tang[1, 2] [1]Program of Genetics & Genome Biology, The Hospital for Sick Children., [2]Department of Molecular Genetics, University of Toronto.	193
14:45 - 16:30	**Remembering the Journey: A DM1 Movies and Stories Session** Tipi-tente-wigwam-Réserve Sud/Nord	
17:30 - 23:59	**Award and Gala Night: Dine, Dance & Celebrate!** La Montagnaise	

Saturday, 30 May 2026

08:30 - 18:30	**Family Day** La Montagnaise